Parexel & Palantir Expand Collaboration to Speed Up Clinical Data Delivery
Parexel & Palantir expand collaboration to accelerate clinical data delivery and patient outcomes Overview
Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of phase I to IV clinical development services, and Palantir Technologies Inc., a leading builder of artificial intelligence (AI) systems, has inked a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers.
Terms of Collaboration
Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigor.
Parexel is the first CRO working with Palantir in this capacity, building on the companies’ existing collaboration over the past year.
Words from Parexel
“As we build on our application of AI to further improve clinical trial execution and advance our offerings in Real World Evidence, advanced analytics and Health Outcomes,” said Jonathan Shough, chief information officer, Parexel.
“Leveraging our internal Parexel expertise and our strategic partnership with Palantir, we have novel solutions already in use or in various stages of development that demonstrate our commitment to be a fully digital CRO.”
Parexel: Leader in the CRO Industry
Parexel is a leader in the CRO industry in enhancing and accelerating the clinical trial lifecycle utilizing its Parexel Precision Pathway, an end-to-end operational approach that prioritizes the timely delivery of clean data while driving efficiency, quality and predictability.
Supported by Palantir’s industry-leading software, Parexel’s clinical data platform provides an integrated digital environment to hyper-automate manual processes, safely promote data discoverability, distill insights from historical trials and streamline coordination among scientific and operational teams and their partners.
Incorporating Foundry and AIP into the Parexel environment will provide Parexel’s customers real-time access to high-quality validated data, ensuring transparency during studies in-flight and condensed timelines from trial planning to submission.
From Parexel’s AI/ML Committee
Stephen Pyke, DIC, chief clinical data and digital officer, Parexel and Chair of the Association of Clinical Research Organization’s (ACRO) AI/ML Committee said “Combining our end-to-end delivery model with Palantir’s world-class security, governance and artificial intelligence platform will generate strategic insights to inform drug development and accelerate time to market.”
Words from Palantir
According to D. Lalarukh Haris Shaikh, executive, life sciences, Palantir. “The company will significantly accelerate its business by tapping the value of data via an ontology constructed within We are delighted to deepen our exceptional collaboration with Parexel, empowering them to fully leverage the capabilities of AIP and Foundry throughout their clinical processes and business operations.